Home » Stocks » BYSI

BeyondSpring, Inc. (BYSI)

Stock Price: $9.67 USD -0.08 (-0.82%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $9.70 +0.03 (0.31%) Jul 26, 6:44 PM
Market Cap 377.77M
Revenue (ttm) 180,000
Net Income (ttm) -60.97M
Shares Out 39.11M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $9.67
Previous Close $9.75
Change ($) -0.08
Change (%) -0.82%
Day's Open 9.73
Day's Range 9.61 - 9.88
Day's Volume 159,791
52-Week Range 9.24 - 17.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announ...

1 week ago - GlobeNewsWire

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announc...

2 weeks ago - GlobeNewsWire

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...

1 month ago - GlobeNewsWire

- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA

1 month ago - GlobeNewsWire

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announc...

1 month ago - GlobeNewsWire

- Data further supports plinabulin's fast onset of action and CIN prevention benefit in week 1 following chemotherapy

1 month ago - GlobeNewsWire

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

1 month ago - GlobeNewsWire

The FDA has accepted for review BeyondSpring Inc's (NASDAQ: BYSI) marketing application seeking approval for the use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for t...

1 month ago - Benzinga

- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021

1 month ago - GlobeNewsWire

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announce...

2 months ago - GlobeNewsWire

- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability.

2 months ago - GlobeNewsWire

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Other stocks mentioned: AVRO, FBIO, XAIR
2 months ago - Zacks Investment Research

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announce...

2 months ago - GlobeNewsWire

- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of...

2 months ago - GlobeNewsWire

- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemotherapy...

2 months ago - GlobeNewsWire

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therap...

2 months ago - GlobeNewsWire

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone

3 months ago - GlobeNewsWire

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

6 months ago - GlobeNewsWire

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

6 months ago - GlobeNewsWire

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

7 months ago - GlobeNewsWire

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.

7 months ago - Seeking Alpha

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

7 months ago - GlobeNewsWire

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smar...

7 months ago - Insider Monkey

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

8 months ago - GlobeNewsWire

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...

8 months ago - GlobeNewsWire

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...

8 months ago - GlobeNewsWire

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...

8 months ago - GlobeNewsWire

- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)

8 months ago - GlobeNewsWire

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...

8 months ago - GlobeNewsWire

- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -

8 months ago - GlobeNewsWire

Former Forty Seven and Roche Senior Executives to Support Partnering Efforts Former Forty Seven and Roche Senior Executives to Support Partnering Efforts

9 months ago - GlobeNewsWire

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology t...

9 months ago - GlobeNewsWire

Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain Poster Pres...

10 months ago - GlobeNewsWire

New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO

10 months ago - GlobeNewsWire

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology can...

10 months ago - GlobeNewsWire

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention o...

10 months ago - GlobeNewsWire

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer thera...

10 months ago - GlobeNewsWire

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: GTHX, KPTI, URGN
11 months ago - Seeking Alpha

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: GTHX, KPTI, URGN
11 months ago - Seeking Alpha

Gilead Acquired Forty Seven in March 2020 for $4.9 Billion Gilead Acquired Forty Seven in March 2020 for $4.9 Billion

11 months ago - GlobeNewsWire

BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster

11 months ago - Seeking Alpha

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

11 months ago - GlobeNewsWire

Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ P...

1 year ago - GlobeNewsWire

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

The company announced the pricing of a public offering of common stock.

1 year ago - The Motley Fool

-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p

1 year ago - GlobeNewsWire

- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN -

1 year ago - GlobeNewsWire

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 2017
Stock Exchange
NASDAQ
Ticker Symbol
BYSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 32.75, which is an increase of 238.68% from the latest price.

Price Target
$32.75
(238.68% upside)
Analyst Consensus: Strong Buy